{"organizations": [], "uuid": "fc8e975f4f726179e1136162f5ee476e9b9114dd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180111.html", "section_title": "Archive News &amp; Video for Thursday, 11 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-theranexus-announces-issuance-of-e/brief-theranexus-announces-issuance-of-european-patent-covering-its-drug-candidate-thn102-for-treatment-of-narcolepsy-and-parkinsons-disease-idUSFWN1P511T", "country": "US", "domain_rank": 408, "title": "BRIEF-Theranexus Announces Issuance Of European Patent Covering Its Drug Candidate THN102 For Treatment Of Narcolepsy and Parkinson's Disease ‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.906, "site_type": "news", "published": "2018-01-11T14:45:00.000+02:00", "replies_count": 0, "uuid": "fc8e975f4f726179e1136162f5ee476e9b9114dd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-theranexus-announces-issuance-of-e/brief-theranexus-announces-issuance-of-european-patent-covering-its-drug-candidate-thn102-for-treatment-of-narcolepsy-and-parkinsons-disease-idUSFWN1P511T", "ord_in_thread": 0, "title": "BRIEF-Theranexus Announces Issuance Of European Patent Covering Its Drug Candidate THN102 For Treatment Of Narcolepsy and Parkinson's Disease ‍​", "locations": [], "entities": {"persons": [{"name": "theranexus", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "treatment of narcolepsy", "sentiment": "neutral"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 11 (Reuters) - THERANEXUS SA:‍​\n* THERANEXUS ANNOUNCES ISSUANCE OF EUROPEAN PATENT COVERING ITS DRUG CANDIDATE THN102 FOR TREATMENT OF NARCOLEPSY AND PARKINSON‘S DISEASE\n* ‍RESULTS ARE EXPECTED IN Q2 OF 2019​ * ‍AT END OF 2017, LAUNCHED REGULATORY ACTIVITIES REQUIRED TO START NEW PHASE II CLINICAL TRIAL FOR THN102 IN 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-11T14:45:00.000+02:00", "crawled": "2018-01-12T18:40:47.012+02:00", "highlightTitle": ""}